BPC-157 vs. BPC-157 / TB-500
Understand how these peptide approaches differ. Neither is FDA-approved as a prescription treatment.
Treatment Class
Synthetic peptide
Peptide combination
How It Works
Derived from a protein found in gastric juice. Studied for potential effects on tissue repair.
Combines BPC-157 with TB-500 (a fragment of thymosin beta-4) for potential complementary effects on recovery.
Common Clinical Uses
Not FDA-approved for any condition. Commonly discussed in research and wellness contexts.
Not FDA-approved for any condition. Commonly discussed in research and wellness contexts.
Administration
Explored in research settings via subcutaneous injection or oral capsule.
Explored in research settings via subcutaneous injection.
Monitoring Considerations
Content pending clinical review. Discuss with a qualified medical provider.
Content pending clinical review. Discuss with a qualified medical provider.
Potential Side Effects
Content pending clinical review. Most evidence is from preclinical (animal) studies.
Content pending clinical review. Most evidence is from preclinical (animal) studies.
Important Considerations
Not FDA-approved. Limited human clinical data. Any use should be discussed with a qualified medical provider.
Not FDA-approved. Combining peptides may have additional considerations. Discuss with a qualified medical provider.
Questions to Discuss With Your Provider
What does the current research say about these peptides?
What are the risks of using non-FDA-approved substances?
What should I consider before exploring peptide therapy?
How do I find a qualified provider to discuss peptide therapy?
Want to discuss these options with a provider?
Start a consultation to discuss which treatment may be appropriate for you.
Start Consultation